These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19422784)

  • 1. Proteomics-based prediction of clinical response in acute myeloid leukemia.
    Albitar M; Potts SJ; Giles FJ; O'Brien S; Jilani I; Donahue AC; Estey EH; Kantarjian H
    Exp Hematol; 2009 Jul; 37(7):784-90. PubMed ID: 19422784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia.
    Albitar M; Potts SJ; Giles FJ; O'Brien S; Keating M; Thomas D; Clarke C; Jilani I; Aguilar C; Estey E; Kantarjian H
    Cancer; 2006 Apr; 106(7):1587-94. PubMed ID: 16518825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of protein profile classification model and screening of proteomic signature of acute leukemia.
    Xu Y; Zhuo J; Duan Y; Shi B; Chen X; Zhang X; Xiao L; Lou J; Huang R; Zhang Q; Du X; Li M; Wang D; Shi D
    Int J Clin Exp Pathol; 2014; 7(9):5569-81. PubMed ID: 25337199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomics of acute myeloid leukaemia: Cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications.
    Balkhi MY; Trivedi AK; Geletu M; Christopeit M; Bohlander SK; Behre HM; Behre G
    Oncogene; 2006 Nov; 25(53):7041-58. PubMed ID: 16732326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomic analysis of childhood de novo acute myeloid leukemia and myelodysplastic syndrome/AML: correlation to molecular and cytogenetic analyses.
    Braoudaki M; Tzortzatou-Stathopoulou F; Anagnostopoulos AK; Papathanassiou C; Vougas K; Karamolegou K; Tsangaris GT
    Amino Acids; 2011 Mar; 40(3):943-51. PubMed ID: 20711619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid/NK cell acute leukemia.
    Chen B; Xu X; Ji M; Lin G
    Int J Hematol; 2009 Apr; 89(3):365-367. PubMed ID: 19326059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia.
    van Dijk AD; Hoff FW; Qiu YH; Chandra J; Jabbour E; de Bont ESJM; Horton TM; Kornblau SM
    Clin Epigenetics; 2021 Jan; 13(1):21. PubMed ID: 33509276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia.
    Pino JC; Posso C; Joshi SK; Nestor M; Moon J; Hansen JR; Hutchinson-Bunch C; Gritsenko MA; Weitz KK; Watanabe-Smith K; Long N; McDermott JE; Druker BJ; Liu T; Tyner JW; Agarwal A; Traer E; Piehowski PD; Tognon CE; Rodland KD; Gosline SJC
    Cell Rep Med; 2024 Jan; 5(1):101359. PubMed ID: 38232702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.
    Bello C; Yu D; Komrokji RS; Zhu W; Wetzstein GA; List AF; Lancet JE
    Cancer; 2011 Apr; 117(7):1463-9. PubMed ID: 21425147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy.
    Dickson GJ; Liberante FG; Kettyle LM; O'Hagan KA; Finnegan DP; Bullinger L; Geerts D; McMullin MF; Lappin TR; Mills KI; Thompson A
    Haematologica; 2013 Aug; 98(8):1216-25. PubMed ID: 23539541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy.
    Kornblau SM; Minden MD; Rosen DB; Putta S; Cohen A; Covey T; Spellmeyer DC; Fantl WJ; Gayko U; Cesano A
    Clin Cancer Res; 2010 Jul; 16(14):3721-33. PubMed ID: 20525753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia.
    Malfuson JV; Etienne A; Turlure P; de Revel T; Thomas X; Contentin N; Terré C; Rigaudeau S; Bordessoule D; Vey N; Gardin C; Dombret H;
    Haematologica; 2008 Dec; 93(12):1806-13. PubMed ID: 18838471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early proteomic analysis may allow noninvasive identification of hepatitis C response to treatment with pegylated interferon α-2b and ribavirin.
    Devitt EJ; Power KA; Lawless MW; Browne JA; Gaora PO; Gallagher WM; Crowe J
    Eur J Gastroenterol Hepatol; 2011 Feb; 23(2):177-83. PubMed ID: 21164346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute Myeloid Leukemia With a Rare t(7;14)(q21;q32) and Trisomy 4 With Poor Clinical Outcome: A Case Report.
    Jabbar SB; Monaghan S; Chen W; Koduru P; Kumar K
    Lab Med; 2017 Nov; 48(4):376-380. PubMed ID: 29069512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The proteogenomic subtypes of acute myeloid leukemia.
    Jayavelu AK; Wolf S; Buettner F; Alexe G; Häupl B; Comoglio F; Schneider C; Doebele C; Fuhrmann DC; Wagner S; Donato E; Andresen C; Wilke AC; Zindel A; Jahn D; Splettstoesser B; Plessmann U; Münch S; Abou-El-Ardat K; Makowka P; Acker F; Enssle JC; Cremer A; Schnütgen F; Kurrle N; Chapuy B; Löber J; Hartmann S; Wild PJ; Wittig I; Hübschmann D; Kaderali L; Cox J; Brüne B; Röllig C; Thiede C; Steffen B; Bornhäuser M; Trumpp A; Urlaub H; Stegmaier K; Serve H; Mann M; Oellerich T
    Cancer Cell; 2022 Mar; 40(3):301-317.e12. PubMed ID: 35245447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic data analysis workflow for discovery of candidate biomarker peaks predictive of clinical outcome for patients with acute myeloid leukemia.
    Forshed J; Pernemalm M; Tan CS; Lindberg M; Kanter L; Pawitan Y; Lewensohn R; Stenke L; Lehtiö J
    J Proteome Res; 2008 Jun; 7(6):2332-41. PubMed ID: 18452325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic analysis of interleukin 6-induced differentiation in mouse myeloid leukemia cells.
    Xia Q; Wang HX; Wang J; Zhang JY; Liu BY; Li AL; Lv M; Hu MR; Yu M; Feng JN; Yang SC; Zhang XM; Shen BF
    Int J Biochem Cell Biol; 2005 Jun; 37(6):1197-207. PubMed ID: 15778084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors in acute myeloid leukemia.
    Avivi I; Rowe JM
    Curr Opin Hematol; 2005 Jan; 12(1):62-7. PubMed ID: 15604893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary excretion of proteolyzed alpha1-antitrypsin: specificity, quantitation, and relation to therapy response in patients with acute myeloid leukemia.
    Dengler R; Plewan A; Münstermann U; Busch R; Eger G; Emmerich B
    Clin Cancer Res; 1995 Feb; 1(2):199-205. PubMed ID: 9815974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial.
    Bouvier A; Hamel JF; Delaunay J; Delabesse E; Dumas PY; Ledoux MP; Peterlin P; Luquet I; Roth Guepin G; Bulabois CE; Gallego Hernanz MP; Guillerm G; Guieze R; Hicheri Y; Simand C; Himberlin C; Hunault-Berger M; Bernard M; Jourdan E; Caillot D; Dorvaux V; Tavernier E; Daguindau E; Banos A; Ojeda-Uribe M; Gyan E; Alexis M; Marolleau JP; Turlure P; Bouscary D; Humbrecht C; Zerazhi H; Béné MC; Pigneux A; Carre M; Ifrah N; Blanchet O; Vey N; Récher C; Cornillet-Lefèbvre P;
    Eur J Haematol; 2021 Jul; 107(1):111-121. PubMed ID: 33765335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.